Analyst consensus rating
CareDx Analyst Rating: Buy
CDNA is rated Buy by 6 analysts with a $52.33 target. As of 2026-08-18.
Direct answer
CareDx's consensus rating is Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $52.33.
Forecast evidence checked August 18, 2026.
Get free CareDx email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $46.05
- Average price target
- $52.33
- High price target
- $64.00
- Low price target
- $40.00
- Low target gap
- -13.1%
- Target upside
- +13.6%
- High target gap
- +39%
- Target range width
- 52.1%
- Consensus rating
- Buy
- Analysts
- 6
- Evidence date
- August 18, 2026
- Valid through
- August 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for CareDx?
CareDx has a verified Buy consensus. The same dataset has an average price target of $52.33.
How far are CareDx's low and high targets from the recorded price?
The low target implies -13.1%, while the high target implies +39%.
How many analysts are included in CareDx's consensus?
The verified consensus includes 6 analysts.
How is CareDx's target upside or downside calculated?
The average target of $52.33 is divided by the recorded price of $46.05, then one is subtracted to produce +13.6%. This does not guarantee a future return.
When was CareDx's analyst forecast verified?
The data was verified on 2026-08-18. The dataset is valid through 2026-08-25.